Access & prescription
Cannabis prescription in Switzerland: who can get one?
Which requirements apply to a cannabis prescription in Switzerland, what the doctor checks and why there is no entitlement to a prescription.
Key points
- Since 1 August 2022, doctors in Switzerland may prescribe cannabis medicines without authorisation from the FOPH. Responsibility for the treatment lies with them.
- There is no statutory list of diseases that trigger a prescription. What matters is whether the prescription is necessary according to the recognised rules of medical science.
- The doctor must have examined you personally and know your state of health. Reports on diagnoses and previous therapies help with this.
- Particular caution is indicated for certain heart and psychiatric conditions, addiction, under 18 years of age and during pregnancy and breastfeeding.
- There is no entitlement to a prescription. Even a prescription does not mean that the health insurer will pay.
You can get a cannabis prescription in Switzerland if, after a medical assessment, you need treatment for which a cannabis medicine is medically justifiable. There is no list of diseases with an automatic entitlement. Since 1 August 2022, doctors decide without authorisation from the Federal Office of Public Health (FOPH) and bear sole responsibility for this.1
Three things are decisive: your doctor must have examined you personally, know your state of health and be able to justify the prescription according to the recognised rules of medicine. Previous treatments play an important role here. A prescription is never guaranteed.3,4,5
Legal situation since 2022: what has changed for the cannabis prescription
With an amendment to the Narcotics Act (BetmG), Parliament lifted the ban on cannabis for medical purposes. It has applied since 1 August 2022. Previously, every treatment required an exceptional authorisation from the FOPH. Today this is no longer necessary: freedom of therapy is guaranteed, and responsibility for the treatment lies exclusively with doctors.1
Nothing has changed for cannabis for non-medical purposes; it remains prohibited.1 The amendment therefore only concerns medical prescription.
New is that prescribing doctors must record every treatment in a digital FOPH reporting system, at the start of therapy and after one and two years. The data are stored in coded form and are used to evaluate the amendment.2
The information in the box comes from the FOPH FAQ.2
Who may issue a cannabis prescription
Prescriptions may be issued by medical professionals who practise their profession under their own professional responsibility and hold a cantonal licence to do so.3 The law does not require a specialisation, for example in pain medicine or neurology. For THC-containing preparations, the doctor must use the official narcotics prescription. According to the Swiss Society for Cannabis in Medicine (SGCM), a normal prescription is sufficient for pure CBD preparations without THC.4,6
Over-the-counter CBD products from shops are not medicines. They cannot be prescribed because they are not subject to quality assurance as a medicine.6
The medical assessment: what the law requires
Three rules determine whether and how a prescription is possible.
- Personal examination. Doctors may only prescribe medicines containing controlled substances to patients they have examined themselves.4
- Known state of health. A medicine may only be prescribed if the patient’s state of health is known.5
- Medical necessity. Narcotics may only be prescribed to the extent necessary according to the recognised rules of medical science.3
It follows that the doctor must know the diagnosis, assess the complaints, check contraindications and interactions and weigh up whether a cannabis medicine is justifiable in your situation. An online questionnaire alone does not meet these requirements.
How well cannabis medicines are supported by evidence varies between diseases. The FOPH notes that sufficient clinical data are not yet available for most possible indications. The SGCM has therefore drawn up treatment recommendations based on the evidence and clinical experience.7
Common areas of use and authorised preparations
The FOPH names the following as the main areas of use for cannabis medicines:2
- chronic pain, for example neuropathic or cancer-related pain
- spasticity or cramps in multiple sclerosis or other neurological diseases
- nausea and loss of appetite during chemotherapy
This list is neither a requirement nor a promise. It describes what cannabis medicines are most frequently prescribed for in practice.
So far, only two cannabis medicines have been authorised by Swissmedic in Switzerland: Sativex® as an add-on therapy for moderate to severe spasticity in multiple sclerosis and Epidyolex® as an add-on therapy for certain forms of childhood epilepsy. In addition, magistral formulations are used, which a pharmacy prepares for a specific person on medical prescription.7 Read more about the differences between dosage forms in the article Dosage forms of medical cannabis.
Documenting previous therapies
The law does not set as a formal condition that other treatments have already been tried. It is, however, part of the medical weighing-up: anyone who must prescribe according to the recognised rules of medicine takes proven treatments into account.3 The FOPH expressly describes magistral formulations as an option for experimental use in patients for whom other treatments have been exhausted.2
The following are therefore helpful for the assessment:
- medical reports with diagnoses, for example from your family doctor, the hospital or a specialist clinic
- an overview of which treatments you have received so far, for how long and with what result
- reasons why a treatment was stopped, such as side effects or lack of effect
- a current list of all medicines, including over-the-counter and herbal ones
Good documentation is also important for a later cost approval from the health insurer. The insurer decides in the individual case after consulting its medical adviser.8
When particular caution applies or a prescription is not an option
The SGCM names only an allergy or hypersensitivity to cannabis, THC, CBD or excipients of the preparation as an absolute contraindication. For THC, it recommends a strict assessment of the indication in:6
- severe cardiovascular diseases, such as coronary heart disease, heart rhythm disorders or after a heart attack
- severe psychiatric illnesses, especially psychoses and panic attacks, even if they occurred in the past
- an existing or previous addiction
- children and adolescents under 18 years of age
The SGCM advises against the use of THC or CBD during pregnancy and breastfeeding.6 In people taking several medicines, possible interactions should be clarified before starting therapy.6 More on this in the articles Cannabis medicine despite pre-existing mental illness and Interactions of THC and CBD.
Mention such points openly in the consultation. They do not rule out therapy in every case, but they change the weighing-up.
No entitlement to a prescription, no guarantee of costs
Because responsibility lies with the doctor, nobody can promise a prescription, either before or after the assessment.1 If the doctor concludes that a cannabis medicine is not justifiable, no prescription is issued.
Even a prescription does not mean that the health insurer will pay. The amendment did not change the conditions for reimbursement; basic health insurance covers cannabis medicines only in exceptional cases.1 The doctor can submit a request for cost approval. According to the SGCM, some insurers require an initially self-funded trial of therapy or cover the costs only for a limited time. Without cost approval, you bear the costs yourself.6,8 The page Costs gives an overview.
An issued narcotics prescription is valid for one month. As a rule, the quantity prescribed may not exceed the requirement for one month. If circumstances justify it, it may cover a maximum of three months.4
How it works at evidena
At evidena, the medical consultation takes place by video. You can book appointments online at portal.evidena.care/appointments. Whether a therapy can be considered for you is assessed exclusively by the doctor in the consultation. If there is no indication, you receive an assessment and pointers to other options, and the first consultation is not charged. The process is described on the page How it works.
If the doctor issues a prescription, it must be filled at a pharmacy within one month. As a rule, the prescribed quantity covers one month, in justified cases at most three months of treatment.4 We answer questions via WhatsApp or at info@evidena.care.
Conclusion
A cannabis prescription in Switzerland requires neither FOPH authorisation nor a specific diagnosis, but it does require a careful medical assessment. The doctor must have examined you, know your state of health and be able to justify the prescription medically. Well-documented previous findings and therapies help with this. There is no entitlement to a prescription.
Frequently asked questions
Do I need FOPH authorisation for a cannabis prescription?
No. Since 1 August 2022, doctors prescribe cannabis medicines without FOPH authorisation, on a narcotics prescription.
Is there a list of diseases for which I will get a prescription?
No. The law does not name any indications. The FOPH lists chronic pain, spasticity in multiple sclerosis and nausea during chemotherapy as the most common areas of use, but what is decisive is the doctor's assessment in the individual case.
Must I have already tried other therapies?
The law does not expressly require this. However, the doctor must follow the recognised rules of medicine, and this includes taking proven treatments into account. Reports on previous therapies are therefore important.
Is a prescription guaranteed if I bring all the documents?
No. Documents make the assessment easier but do not replace the doctor's decision. There is no entitlement to a prescription.
Who may issue a cannabis prescription?
Doctors with a cantonal licence to practise. A particular medical specialty is not required.
Sources
- Gesetzesänderung Cannabisarzneimittel, Bundesamt für Gesundheit BAG, ohne Datum (accessed 13 November 2026)
- FAQ Cannabisarzneimittel, Bundesamt für Gesundheit BAG, 4. März 2025 (accessed 13 November 2026)
- Betäubungsmittelgesetz (BetmG), SR 812.121, Art. 9, 10 und 11, Fedlex (accessed 13 November 2026)
- Betäubungsmittelkontrollverordnung (BetmKV), SR 812.121.1, Art. 46 und 47, Fedlex (accessed 13 November 2026)
- Heilmittelgesetz (HMG), SR 812.21, Art. 26, Fedlex (accessed 13 November 2026)
- Allgemeine Informationen zur Anwendung von Medizinalcannabis für Fachpersonen (Fachinformation), Schweizerische Gesellschaft für Cannabis in der Medizin SGCM, ohne Datum (Dateipfad 2024/06), S. 5, 6, 7, 13 und 14 (accessed 13 November 2026)
- Behandlungsempfehlungen für den Einsatz von Cannabisarzneimitteln, Bundesamt für Gesundheit BAG, 17. Januar 2025 (accessed 13 November 2026)
- Verordnung über die Krankenversicherung (KVV), SR 832.102, Art. 71a bis 71d, Fedlex (accessed 13 November 2026)